Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3181
-$0.0359-10.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -37.50% | -98.93% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -37.50% | -98.93% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -37.50% | -98.93% | -- | -- |
| SG&A Expenses | -49.39% | -23.88% | 3.17% | -3.72% | -12.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.09% | -68.12% | -42.11% | -40.10% | -39.05% |
| Operating Income | 65.90% | 68.20% | 38.54% | 40.50% | 39.40% |
| Income Before Tax | 67.36% | 67.66% | 39.19% | 39.64% | 36.74% |
| Income Tax Expenses | 382.94% | 68.56% | 29.69% | -2.58% | 73.31% |
| Earnings from Continuing Operations | 42.10% | 67.56% | 40.22% | 49.24% | 28.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.10% | 67.56% | 40.22% | 49.24% | 28.95% |
| EBIT | 65.90% | 68.20% | 38.54% | 40.50% | 39.40% |
| EBITDA | 65.86% | 68.18% | 38.49% | 40.46% | 39.44% |
| EPS Basic | 94.70% | 87.40% | 72.54% | 67.58% | 30.27% |
| Normalized Basic EPS | 96.99% | 87.33% | 71.81% | 61.12% | 38.08% |
| EPS Diluted | 94.70% | 87.40% | 72.54% | 67.58% | 30.27% |
| Normalized Diluted EPS | 96.99% | 87.33% | 71.81% | 61.12% | 38.08% |
| Average Basic Shares Outstanding | 982.25% | 155.33% | 115.73% | 55.26% | 2.17% |
| Average Diluted Shares Outstanding | 982.25% | 155.33% | 115.73% | 55.26% | 2.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -0.41% |